Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BSH 2022 | COVID-19 vaccine effectiveness in transplant patients

Keith Wilson • 4 Apr 2022
BSH 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma

In this video, Keith Wilson, MBBS, FRCP, FRCPath, Cardiff University, Cardiff and Vale University Health Board, Cardiff, Wales, briefly discusses patient response to COVID-19 vaccination post-transplantation, and the potential impact of booster vaccines. Dr Wilson explains that there is not enough data regarding the efficacy of vaccination in these highly vulnerable patients, making it difficult to give clear guidance to patients and the need for more data in this area. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

More from Keith Wilson

Using prehabilitation to improve patient outcome post-transplant
2:07
Using prehabilitation to improve patient outcome post-transplant
Keith Wilson • 4 Apr 2022
Managing post-transplant complications in patients with DLBCL
1:38
Managing post-transplant complications in patients with DLBCL
Keith Wilson • 4 Apr 2022
Improving second-line treatments in DLBCL
0:58
Improving second-line treatments in DLBCL
Keith Wilson • 4 Apr 2022
Autologous transplantation in DLBCL and unmet needs
0:44
Autologous transplantation in DLBCL and unmet needs
Keith Wilson • 4 Apr 2022

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals